1
|
Dang C, Ewer MS, Delaloge S, Ferrero JM, Colomer R, de la Cruz-Merino L, Werner TL, Dadswell K, Verrill M, Eiger D, Sarkar S, de Haas SL, Restuccia E, Swain SM. BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers (Basel) 2022; 14:cancers14112596. [PMID: 35681574 PMCID: PMC9179451 DOI: 10.3390/cancers14112596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Revised: 04/21/2022] [Accepted: 04/22/2022] [Indexed: 01/03/2023] Open
Abstract
BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant−adjuvant pertuzumab−trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients received dose-dense doxorubicin and cyclophosphamide q2w × 4 ➝ paclitaxel qw × 12 (Cohort A) or 5-fluorouracil, epirubicin, cyclophosphamide q3w × 4 ➝ docetaxel q3w × 4 (B) as per physician’s choice. Pertuzumab−trastuzumab (q3w) was initiated from the taxane start and continued post-surgery to complete 1 year. Median follow-up: 64.5 months. There were no new cardiac issues and a low incidence of Class III/IV heart failure (Cohort B only: one patient (0.5%) in the adjuvant and treatment-free follow-up (TFFU) periods). Fourteen patients (7.7%) had LVEF declines of ≥10% points from baseline to <50% in Cohort A, as did 20 (10.5%) in B during the adjuvant period (12 (6.2%) in A and 7 (3.6%) in B during TFFU). The five-year event-free survival rates in Cohorts A and B were 90.8% (95% CI: 86.5, 95.2) and 89.2% (84.8, 93.6), respectively. The five-year overall survival rates were 96.1% (95% CI: 93.3, 98.9) and 93.8% (90.3, 97.2), respectively. The final analysis of BERENICE further supports pertuzumab−trastuzumab-based therapies as standard of care for high-risk, HER2-positive EBC.
Collapse
Affiliation(s)
- Chau Dang
- Department of Medicine, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Correspondence: ; Tel.: +1-646-888-5426
| | - Michael S. Ewer
- Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Suzette Delaloge
- Department of Medical Oncology, Institut Gustave Roussy, 94805 Paris, France;
| | - Jean-Marc Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, University Côte d’Azur, 06110 Nice, France;
| | - Ramon Colomer
- Division of Medical Oncology, Hospital Universitario La Princesa, 28006 Madrid, Spain;
| | - Luis de la Cruz-Merino
- Department of Clinical Oncology, Hospital Universitario Virgen Macarena, 41009 Seville, Spain;
| | - Theresa L. Werner
- Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA;
| | - Katherine Dadswell
- Global Product Development, Roche Products Limited, Welwyn Garden City AL7 1TW, UK;
| | - Mark Verrill
- Northern Centre for Cancer Care, Freeman Hospital, Newcastle-upon-Tyne NE7 7DN, UK;
| | - Daniel Eiger
- Product Development Oncology, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland; (D.E.); (E.R.)
| | - Sriparna Sarkar
- External Business Partner, Roche Products Limited, Welwyn Garden City AL7 1TW, UK;
| | - Sanne Lysbet de Haas
- Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland;
| | - Eleonora Restuccia
- Product Development Oncology, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland; (D.E.); (E.R.)
| | - Sandra M. Swain
- Georgetown University Medical Center, Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC 20007, USA;
| |
Collapse
|